We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

49 hedge funds and large institutions have $8.04M invested in Palvella Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,000% more call options, than puts

Call options by funds: $21K | Put options by funds: $1K

0.17% more ownership

Funds ownership: 0.58% → 0.74% (+0.17%)

18% less funds holding

Funds holding: 60 → 49 (-11)

59% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 17

65% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 17

76% less capital invested

Capital invested by funds: $33.4M → $8.04M (-$25.4M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
49
Holders Change
-11
Holders Change %
-18.33%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
7
Reduced
17
Closed
17
Calls
$21K
Puts
$1K
Net Calls
+$20K
Net Calls Change
-$67K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$11.8M
2
OCA
Octagon Capital Advisors
New York
+$4.77M
3
LCM
Lynx1 Capital Management
Puerto Rico
+$2.05M
4
SCM
Silverarc Capital Management
Massachusetts
+$729K
5
CM
CM Management
Florida
+$417K

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$4.04M
2
Marshall Wace
Marshall Wace
United Kingdom
-$2.22M
3
PIM
Platinum Investment Management
Australia
-$952K
4
ACM
Aquilo Capital Management
California
-$947K
5
Walleye Capital
Walleye Capital
New York
-$467K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCB
51
Cutter & Co Brokerage
Missouri
– -$370K -4,718 Closed
CS
52
Candriam SCA
Luxembourg
– -$316K -4,398 Closed
AAA
53
Affinity Asset Advisors
New York
– -$300K -3,837 Closed
BCM
54
Bridgeway Capital Management
Texas
– -$114K -1,456 Closed
Dimensional Fund Advisors
55
Dimensional Fund Advisors
Texas
– -$96.8K -1,240 Closed
Millennium Management
56
Millennium Management
New York
– -$78K -998 Closed
Connor, Clark & Lunn Investment Management (CC&L)
57
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$68.5K -878 Closed
Bank of America
58
Bank of America
North Carolina
– -$21.7K -278 Closed
BRWA
59
B. Riley Wealth Advisors
Florida
– -$18.5K -238 Closed
William Blair & Company
60
William Blair & Company
Illinois
– -$18.1K -232 Closed
Susquehanna International Group
61
Susquehanna International Group
Pennsylvania
– -$15.5K -199 Closed
JMF
62
Johnson Midwest Financial
Iowa
– -$781 -10 Closed
TWA
63
TCI Wealth Advisors
Arizona
– -$196 -3 Closed
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
– +$1.88K +31 New
1 2
3

PVLA Hedge Fund Activity: Q2 2023 in Review

49 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2023, worth a combined $8.04M — down 76% from $33.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PVLA and 6 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 7 added.

The largest buyer was BVF Inc, adding an estimated $11.8M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $4.04M sold.

  • 49 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2023, down from 60 in Q1 2023.
  • Funds reported $8.04M of Palvella Therapeutics stock for Q2 2023, down 76% quarter-over-quarter.
  • 6 funds opened new Palvella Therapeutics positions in Q2 2023 and 17 closed out, a net change of -11 holders.
  • The largest Palvella Therapeutics buyer in Q2 2023 was BVF Inc, an estimated $11.8M added.
  • The largest Palvella Therapeutics seller in Q2 2023 was Soleus Capital Management, an estimated $4.04M sold.

Based on aggregated 13F filings for Q2 2023.